secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2026-07-20T10:05:18+00:00
Accession:  0001493152-26-033829
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma terminates Richard Graydon; management sees no material impact
------------------------------------------------------------------------------

- Richard Graydon terminated effective July 17, 2026, for reasons unrelated to his company activities.
- Management states Graydon's short tenure means no material effect on the business.
- No replacement or further details on Graydon's role were disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315226033829/0001493152-26-033829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315226033829/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-033829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer